Report cover image

Mild Cognitive Impairment Drug Pipeline Analysis Report 2025

Publisher Expert Market Research
Published May 25, 2025
Length 200 Pages
SKU # EMAR20146982

Description

Mild cognitive impairment (MCI) refers to a neurocognitive disorder that is characterized by memory and thinking problems. The slight decline in mental abilities is more severe than normal aging but less severe compared to dementia. It is estimated that around 12 to 18% of individuals aged 60 years or above are living with mild cognitive impairment, with approximately 10 to 15%  of patients developing dementia annually. Thus, the rising incidence of mild cognitive impairment, particularly among older adults, is expected to drive the drug pipeline expansion in the coming years.

Report Coverage

The Mild Cognitive Impairment Drug Pipeline Report by Expert Market Research gives comprehensive insights into mild cognitive impairment drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for mild cognitive impairment. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The mild cognitive impairment pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from mild cognitive impairment.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing mild cognitive impairment pipeline development activities.

Mild Cognitive Impairment Drug Pipeline Outlook

In mild cognitive impairment, people experience trouble with memory, language, and judgment. The cognitive decline does not affect the patient’s ability to perform everyday activities but is serious enough to be noticed by the affected individual or their family or friends. Mild cognitive impairment is classified into amnestic (affects primarily memory) and nonamnestic MCI (affects thinking abilities other than memory). Mild cognitive impairment can be an early stage of Alzheimer’s disease.

Currently, there is no standard mild cognitive impairment treatment or approved drugs. Robust efforts by pharmaceutical companies to develop novel therapies and innovations in diagnostic techniques such as neuroimaging and biomarker analysis are anticipated to advance medical care for this condition. Moreover, the rising interest of health regulatory bodies such as the U.S. Food and Drug Administration (FDA) in accelerating the approval of drugs for cognitive impairment and Alzheimer’s is likely to support pipeline expansion.

Mild Cognitive Impairment – Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of mild cognitive impairment drug candidates based on several segmentations including:

By Phase

EMR’s pipeline assessment report covers 50+ drug analyses based on phase:
  • Late-Stage Products (Phase 3 and Phase 4)
  • Mid-Stage Products (Phase 2)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products
By Drug Class

EMR’s mild cognitive impairment therapeutic assessment report covers 50+ drug analyses based on drug classes:
  • Small Molecules
  • Monoclonal Antibodies
  • Synthetic Peptides
  • Antibodies
  • Cell Therapies
  • Gene Therapies
  • Recombinant Proteins
  • Subunit Vaccines
By Route of Administration

EMR’s pipeline assessment report covers 50+ drug analyses based on the route of administration:
  • Oral
  • Parenteral
  • Others
Mild Cognitive Impairment – Pipeline Assessment Segmentation, By Phases

The mild cognitive impairment report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials for mild cognitive impairment, with around 69 drugs undergoing phase II clinical development.

Mild Cognitive Impairment – Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the mild cognitive impairment pipeline analysis include small molecules, monoclonal antibodies, synthetic peptides, antibodies, cell therapies, gene therapies, recombinant proteins, and subunit vaccines. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for mild cognitive impairment.

Mild Cognitive Impairment Clinical Trials Therapeutic Assessment – Competitive Dynamics

The EMR mild cognitive impairment drug report insights cover the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in mild cognitive impairment clinical trials:
  • MTI Biotech Inc
  • Novartis Pharmaceuticals
  • Aptinyx
  • Biogen
  • Keymed Biosciences Co.Ltd
  • Merck Sharp & Dohme LLC
  • Eli Lilly and Company
Mild Cognitive Impairment – Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for mild cognitive impairment. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of mild cognitive impairment drug candidates.

Drug: Spironolactone

The objective of the clinical trial is to evaluate the efficacy and safety of a blood pressure medication, spironolactone, for the treatment of mild cognitive impairment and early dementia in African American patients. The study is under Phase IV clinical development and has an estimated 30 participants.

Drug: Atorvastatin

This Phase II clinical study is aimed at evaluating the effects of the mild cognitive impairment drug candidate atorvastatin on brain vessel reactivity along with blood flow in people with mild cognitive impairment. The interventional study has enrolled about 20 subjects and is expected to be completed by December 2026.

Reasons To Buy This Report

The Mild Cognitive Impairment Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for mild cognitive impairment. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into mild cognitive impairment collaborations, regulatory environments, and potential growth opportunities within mild cognitive impairment pipeline insights.

Key Questions Answered in the Mild Cognitive Impairment – Pipeline Insight Report
  • Which companies/institutions are leading the mild cognitive impairment drug development?
  • What is the efficacy and safety profile of mild cognitive impairment pipeline drugs?
  • Which company is leading the mild cognitive impairment pipeline development activities?
  • What is the current mild cognitive impairment commercial assessment?
  • What are the opportunities and challenges present in the mild cognitive impairment drug pipeline landscape?
  • What is the efficacy and safety profile of mild cognitive impairment pipeline drugs?
  • Which company is conducting major trials for mild cognitive impairment drugs?
  • Which companies/institutions are involved in mild cognitive impairment collaborations aimed at providing enhanced therapeutic alternatives for patients?
  • What are the geographies covered for clinical trials in mild cognitive impairment?
Related Reports

Mild Cognitive Impairment (MCI) Market

Global Clinical Trials Market

Table of Contents

200 Pages
1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology & Assumptions
2 Executive Summary
3 Overview of Mild Cognitive Impairment
3.1 Signs and Symptoms
3.2 Causes
3.3 Risk Factors
3.4 Types of Mild Cognitive Impairment
3.5 Diagnosis
3.6 Treatment
4 Patient Profile: Mild Cognitive Impairment
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Mild Cognitive Impairment: Epidemiology Snapshot
5.1 Mild Cognitive Impairment Incidence by Key Markets
5.2 Mild Cognitive Impairment – Patients Seeking Treatment in Key Markets
6 Mild Cognitive Impairment: Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
7 Mild Cognitive Impairment: Key Facts Covered
7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
7.2 Top Countries Contributing to Clinical Trials in Europe
7.3 Top Countries Contributing to Clinical Trials in North America
7.4 Top Countries Contributing to Clinical Trials in Other Regions
8 Mild Cognitive Impairment, Drug Pipeline Assessment
8.1 Assessment by Treatment Type
8.2 Assessment by Route of Administration
8.3 Assessment by Drug Class
9 EMR Drug Pipeline Comparative Analysis
9.1 List of Mild Cognitive Impairment Pipeline Drugs
9.1.1 By Company
9.1.2 By Phase
9.1.3 By Indication
9.1.4 By Trial Status
9.1.5 By Funder Type
9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
10 Mild Cognitive Impairment Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
10.1 Comparative Analysis for Late-Stage Drugs
10.1.1 Study Type
10.1.2 Recruitment Status
10.1.3 Company
10.1.4 Funder Type
10.2 Product Level Analysis*
10.2.1 Drug: Spironolactone
10.2.1.1 Product Description
10.2.1.2 Trial ID
10.2.1.3 Sponsor Name
10.2.1.4 Study Type
10.2.1.5 Drug Class
10.2.1.6 Eligibility Criteria
10.2.1.7 Study Record Dates
10.2.1.7.1 First Submitted
10.2.1.7.2 First Posted
10.2.1.7.3 Last Update Posted
10.2.1.7.4 Last Verified
10.2.1.8 Indication
10.2.1.9 Study Design
10.2.1.10 Recruitment Status
10.2.1.11 Enrollment (Estimated)
10.2.1.12 Location Countries
10.2.1.13 Recent Results
10.2.2 Drug: extended release metformin
10.2.3 Drug: Ginkgo Biolba Extract Fifty
10.2.4 Other Drugs
11 Mild Cognitive Impairment Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
11.1 Comparative Analysis for Mid-Stage Drugs
11.1.1 Study Type
11.1.2 Recruitment Status
11.1.3 Company
11.1.4 Funder Type
11.2 Product Level Analysis*
11.2.1 Drug: Lamivudine 300 MG
11.2.1.1 Product Description
11.2.1.2 Trial ID
11.2.1.3 Sponsor Name
11.2.1.4 Study Type
11.2.1.5 Drug Class
11.2.1.6 Eligibility Criteria
11.2.1.7 Study Record Dates
11.2.1.7.1 First Submitted
11.2.1.7.2 First Posted
11.2.1.7.3 Last Update Posted
11.2.1.7.4 Last Verified
11.2.1.8 Indication
11.2.1.9 Study Design
11.2.1.10 Recruitment Status
11.2.1.11 Enrollment (Estimated)
11.2.1.12 Location Countries
11.2.1.13 Recent Results
11.2.2 Drug: Atorvastatin Oral Tablet
11.2.3 Other Drugs
12 Mild Cognitive Impairment Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
12.1 Comparative Analysis for Early-Stage Drugs
12.1.1 Study Type
12.1.2 Recruitment Status
12.1.3 Company
12.1.4 Funder Type
12.2 Product Level Analysis*
12.2.1 Drug: 2-hydroxybenzylamine acetate
12.2.1.1 Product Description
12.2.1.2 Trial ID
12.2.1.3 Sponsor Name
12.2.1.4 Study Type
12.2.1.5 Drug Class
12.2.1.6 Eligibility Criteria
12.2.1.7 Study Record Dates
12.2.1.7.1 First Submitted
12.2.1.7.2 First Posted
12.2.1.7.3 Last Update Posted
12.2.1.7.4 Last Verified
12.2.1.8 Indication
12.2.1.9 Study Design
12.2.1.10 Recruitment Status
12.2.1.11 Enrollment (Estimated)
12.2.1.12 Location Countries
12.2.2 Drug: NIO752
12.2.3 Other Drugs
13 Mild Cognitive Impairment Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
13.1.1 Study Type
13.1.2 Recruitment Status
13.1.3 Company
13.1.4 Funder Type
13.2 Product Level Analysis*
13.2.1 Drug 1
13.2.1.1 Product Description
13.2.1.2 Trial ID
13.2.1.3 Sponsor Name
13.2.1.4 Study Type
13.2.1.5 Drug Class
13.2.1.6 Eligibility Criteria
13.2.1.7 Study Record Dates
13.2.1.7.1 First Submitted
13.2.1.7.2 First Posted
13.2.1.7.3 Last Update Posted
13.2.1.7.4 Last Verified
13.2.1.8 Indication
13.2.1.9 Study Design
13.2.1.10 Recruitment Status
13.2.1.11 Enrollment (Estimated)
13.2.1.12 Location Countries
13.2.2 Other Drugs
14 Mild Cognitive Impairment, Key Drug Pipeline Companies
14.1 MTI Biotech Inc
14.1.1 Company Snapshot
14.1.2 Pipeline Product Portfolio
14.1.3 Financial Analysis
14.1.4 Recent News and Developments
14.2 Novartis Pharmaceuticals
14.2.1 Company Snapshot
14.2.2 Pipeline Product Portfolio
14.2.3 Financial Analysis
14.2.4 Recent News and Developments
14.3 Aptinyx
14.3.1 Company Snapshot
14.3.2 Pipeline Product Portfolio
14.3.3 Financial Analysis
14.3.4 Recent News and Developments
14.4 Biogen
14.4.1 Company Snapshot
14.4.2 Pipeline Product Portfolio
14.4.3 Financial Analysis
14.4.4 Recent News and Developments
14.5 Keymed Biosciences Co. Ltd
14.5.1 Company Snapshot
14.5.2 Pipeline Product Portfolio
14.5.3 Financial Analysis
14.5.4 Recent News and Developments
14.6 Merck Sharp & Dohme LLC
14.6.1 Company Snapshot
14.6.2 Pipeline Product Portfolio
14.6.3 Financial Analysis
14.6.4 Recent News and Developments
14.7 Eli Lilly and Company
14.7.1 Company Snapshot
14.7.2 Pipeline Product Portfolio
14.7.3 Financial Analysis
14.7.4 Recent News and Developments
15 Regulatory Framework for Drug Approval, By Region
16 Terminated or Suspended Pipeline Products

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us